Karyopharm Therapeutics | KPTI - Operating Expenses


Karyopharm Therapeutics reported $61.83M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
AbbVie USD 10.27B 1000K Jun/2026
Abbott USD 10.46B 1.15B Jun/2026
Amgen USD 11.69B 6.9B Jun/2026
AstraZeneca USD 12.22B 4.04B Jun/2026
BioCryst Pharmaceuticals USD 119.78M 673.63M Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Eli Lilly USD 10.52B 496M Jun/2026
Enanta Pharmaceuticals USD 126.59M 346.51M Dec/2025
GlaxoSmithKline GBP 5.8B 468M Jun/2026
Incyte USD 973.64M 4.65B Jun/2026
J&J USD 17.83B 388M Jun/2026
Karyopharm Therapeutics USD 61.83M 9.9M Mar/2026
MacroGenics USD 42.87M 21.68M Jun/2026
Merck USD 15.77B 2.4B Jun/2026
Nektar Therapeutics USD 49.12M 8.22M Mar/2026
Novartis USD 10.2B 912M Jun/2026
Novartis USD 9.29B 507M Mar/2026
Pfizer USD 85.19B 4.91B Jun/2026
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Takeda JPY 1.02T 89.68B Jun/2026
Tectonic Therapeutic USD 27.3M 5.78M Mar/2026
TG Therapeutics USD 218.66M 48.54M Jun/2026
Ultragenyx Pharmaceutical USD 289M 16M Jun/2026
Xencor USD 87.82M 5.44M Jun/2026